Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum.

Minshall RD, Nedumgottil SJ, Igić R, Erdös EG, Rabito SF.

Peptides. 2000 Aug;21(8):1257-64.

PMID:
11035213
3.

In vitro and in vivo characterization of bradykinin B2 receptors in the rabbit and the guinea pig.

Gobeil F, Filteau C, Pheng LH, Jukic D, Nguyen-Le XK, Regoli D.

Can J Physiol Pharmacol. 1996 Feb;74(2):137-44.

PMID:
8723025
4.

Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin.

Erdös EG, Jackman HL, Brovkovych V, Tan F, Deddish PA.

J Mol Cell Cardiol. 2002 Dec;34(12):1569-76. Review.

PMID:
12505055
5.

Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.

Ianzer D, Santos RA, Etelvino GM, Xavier CH, de Almeida Santos J, Mendes EP, Machado LT, Prezoto BC, Dive V, de Camargo AC.

J Pharmacol Exp Ther. 2007 Aug;322(2):795-805. Epub 2007 May 2.

PMID:
17475904
7.

In vitro and in vivo effects of the new nonpeptide bradykinin B2 receptor antagonist, LF 16-0335C, on guinea-pig and rat kinin receptors.

Pruneau D, Luccarini JM, Fouchet C, Defrêne E, Franck RM, Loillier B, Duclos H, Robert C, Cremers B, Bélichard P, Paquet JL.

Fundam Clin Pharmacol. 1999;13(1):75-83.

PMID:
10027091
8.
9.

ACE inhibitor potentiation of bradykinin-induced venoconstriction.

Hecker M, Blaukat A, Bara AT, Müller-Esterl W, Busse R.

Br J Pharmacol. 1997 Aug;121(7):1475-81.

10.

Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor.

Deddish PA, Marcic BM, Tan F, Jackman HL, Chen Z, Erdös EG.

Hypertension. 2002 Feb;39(2 Pt 2):619-23.

PMID:
11882619
11.

Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.

Sivieri DO Jr, Bispo-da-Silva LB, Oliveira EB, Resende AC, Salgado MC.

Hypertension. 2007 Jul;50(1):110-5. Epub 2007 Apr 30.

PMID:
17470724
12.

Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I.

Greco AJ, Master RG, Fokin A Jr, Baber SR, Kadowitz PJ.

Can J Physiol Pharmacol. 2006 Nov;84(11):1163-75.

PMID:
17218981
13.

Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery.

Miyamoto A, Murata S, Nishio A.

Naunyn Schmiedebergs Arch Pharmacol. 2002 May;365(5):365-70. Epub 2002 Mar 19.

PMID:
12012022
14.

Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997.

Asano M, Hatori C, Sawai H, Johki S, Inamura N, Kayakiri H, Satoh S, Abe Y, Inoue T, Sawada Y, Mizutani T, Oku T, Nakahara K.

Br J Pharmacol. 1998 Jun;124(3):441-6.

16.

Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells.

Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B, Erdös EG.

Circ Res. 1997 Nov;81(5):848-56. Erratum in: Circ Res 1998 Jan 9-23;82(1):137.

PMID:
9351459
17.

Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor.

Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdös EG.

J Biol Chem. 2002 May 10;277(19):16847-52. Epub 2002 Mar 5.

18.

Enhancement of bradykinin and resensitization of its B2 receptor.

Marcic B, Deddish PA, Jackman HL, Erdös EG.

Hypertension. 1999 Mar;33(3):835-43.

PMID:
10082496
19.
20.

Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation.

Dendorfer A, Reibetamann S, Wolfrum S, Raasch W, Dominiak P.

Hypertension. 2001 Jul;38(1):142-6.

PMID:
11463775

Supplemental Content

Support Center